Sanoïa
Sanoïa is a French digital contract research organization that designs and runs tailor-made real-world clinical studies on a proprietary e-CRF platform with native SNDS analytics, serving pharmaceutical, biotech, MedTech and patient-association sponsors. Since July 2024 it operates as a majority-owned subsidiary of Groupe Astek.
- Company typePrivate
- Founded2010
- HeadquartersGémenos, France
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Sanoïa does
Sanoïa, operating legally as e-Health Services Sanoïa S.A.S. (RCS Marseille 528233190), is a French contract research organization founded in 2010 in Aubagne by Hervé Servy and Naïma Hamamouche and now headquartered in Gémenos. The firm specializes in tailor-made real-world clinical studies for pharmaceutical, biotech, MedTech and digital-therapeutic sponsors, with deep practice in rheumatology, diabetology, immunology, oncology and gastroenterology, and additional work for patient associations and academic consortia.
Its core product is a proprietary digital CRO platform anchored on an electronic Case Report Form (e-CRF) deployable in days, supporting multi-modal data capture (secure email, fax, PDF upload, web/mobile entry), investigator-center portals with priority query routing, a patient Personal Health Record, and real-time analytics dashboards. A native integration with the French Système National des Données de Santé (SNDS), the EGB sample, and open health datasets (Open DAMIR, Open PHMEV, Open Medic, Open Bio, Open LPP, Géodes, ScanSanté) underpins its real-world evidence practice. The platform runs on a CNIL-registered DPO (DPO-248) and approved French health-data hosting (Hébergement agréé données de santé), and is augmented by an "Agile Network" of hyper-specialized partners in AI, sociology, biometrics and e-learning mobilized per study.
Sanoïa sells full-service bespoke CRO engagements on a project-scoped, quote-based model with multi-year contracts and no public pricing. The go-to-market is sales-led enterprise field sales to French and European sponsors, supplemented by event-driven scientific visibility (EULAR, SFR, JNLF, SFE) and channel-distributed after the July 2024 majority acquisition by Groupe Astek, which integrates Sanoïa into Astek's Life Sciences Business Line (>13% of Astek group revenue) for cross-sell and international expansion. Pre-acquisition organic growth was reported above 20% per year.
Sanoïa firmographics
Firmographics- Name
- Sanoïa
- Legal name
- e-Health Services Sanoïa
- Website
- https://sanoia-digital-cro.com
- Company type
- Private
- Founded year
- 2010
- Operating status
- Acquired
- Headcount range
- 11–50 employees
- Short description
- Sanoïa is a French digital contract research organization that designs and runs tailor-made real-world clinical studies on a proprietary e-CRF platform with native SNDS analytics, serving pharmaceutical, biotech, MedTech and patient-association sponsors. Since July 2024 it operates as a majority-owned subsidiary of Groupe Astek.
- Ownership category
- akta.pro rank
Sanoïa industry classification
Industry- Product category
- Contract Research Organization (CRO) Services
- NAICS
- Scientific Research and Development Services (5417)
- SIC
- Services-Engineering, Accounting, Research, Management (8700)
- akta.pro primary industry
- Clinical CROs (Phase I–IV) (HLAGAAAA)
- akta.pro secondary industry
- Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL)
Keywords
Where Sanoïa is headquartered
LocationHeadquarters
- HQ city
- Gémenos
- HQ country
- France
- HQ region
- Europe
Offices2 records
Markets served
Sanoïa business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Full-service CRO contracts for real-world studies: Project-based service contracts covering the full lifecycle of real-world clinical studies (RWD) and non-interventional studies (NIS) for pharmaceutical, biotech and MedTech sponsors — including co-design, regulatory, medical writing, site management/monitoring, biometrics, digitization, patient contact and SNDS analytics. Delivered in France and internationally; organic growth cited at >20% per year pre-acquisition.
- Managed digital CRO services (managed services for sponsors): Ongoing managed digital CRO delivery including platform hosting, dashboards, patient engagement, e-cohort operations and long-term SNDS-linked follow-up (e.g., PERFUSE biosimilar study, AWAIR ambispective international study).
- Specialized digital & patient-experience solutions: Discrete solution offerings for patient associations (questionnaires, SNDS linkage) and pharmaceutical/MedTech clients (biosimilar studies, innovative drug studies, medical device/DTx studies, questionnaires).
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Custom project-based CRO quotes |
Go-to-market motion4 records
Distribution channels5 records
Marketing channels6 records
Sanoïa product offering
Product offeringCore offering
Sanoïa is a digital Contract Research Organization (CRO) that designs, conducts and manages real-world clinical studies for pharmaceutical, biotech and MedTech sponsors. The company combines a proprietary digital platform (e-CRF, patient and investigator portals, multi-modal data capture) with full-service clinical operations (co-design, regulatory, medical writing, monitoring, biometrics, patient contact, SNDS/EGB analytics) to deliver decentralized, patient-centric real-world evidence studies in France and Europe.
Differentiator
Problem solved
Functional benefit
Products and services
- Sanoïa Full-Service Digital CRO End-to-end contract research offering covering co-design, regulatory affairs, medical writing, clinical operations management, site monitoring, biometrics, digitization of processes, patient contact and SNDS analytics for pharmaceutical, biotech, MedTech and academic sponsors conducting real-world clinical studies.
- SNDS / EGB / e-cohorte Analytics Solutions Service offering for retrieving, processing and linking data from the French Système National des Données de Santé (SNDS) and Échantillon Généraliste de Bénéficiaires (EGB) to build real-world e-cohorts and generate real-world evidence for sponsors.
- Patient Association Questionnaires Solution Solution package for patient associations to deploy questionnaires and capture patient-reported outcomes with early and transparent participation in clinical research.
- Patient Association SNDS Solution Solution package for patient associations that combines patient questionnaire data with French national health database (SNDS) access to generate real-world evidence on patient populations.
- Pharmaceutical Industry Biosimilars Solution Solution package for pharmaceutical-industry clients developing biosimilars, supporting real-world evidence generation across rheumatic and gastrointestinal indications (as demonstrated by the PERFUSE adalimumab biosimilar SB5 study).
- Pharmaceutical Industry Innovative Medicines Solution Solution package for pharmaceutical-industry clients developing innovative medicines, providing real-world clinical study design, conduct, and analytics across therapeutic areas.
- Pharmaceutical Industry Questionnaires Solution Solution package deploying patient questionnaires and patient-reported outcome instruments for pharmaceutical-industry clients conducting real-world clinical studies.
- MedTech Medical Devices Solution Solution package for MedTech and medical-device clients, supporting clinical studies and real-world evidence generation for medical devices and digital therapeutics (DTx).
Quantifiable outcome
- Stand-up of the FAI2R COVID-19 e-cohort in 15 days using Sanoïa's digital tools
- +6 more outcomes
Companies that use Sanoïa
Customer profileSegments4 records
Ideal customer profiles3 records
Sanoïa technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration5 records
AI capability9 records
Feature7 records
Sanoïa partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered minor and core.
- Bpifrance — Communauté en Santé NumériqueminorSanoïa joined the Bpifrance Digital Health Community ("Communauté en Santé Numérique de Bpifrance") in April 2021 — a French public-investment-bank ecosystem for digital health actors.
- FAI2R / SFR / SOFREMIP / IMIDIATE / CRI / SNFMI consortiumcorePro-bono deployment of Sanoïa's digital tools to a French scientific consortium for the RMD COVID-19 cohort (FAI2R et al.), enabling multi-modal data capture and real-time analytics dashboards on autoimmune/inflammatory disease patients with suspected or confirmed COVID-19.
- Air Liquide HealthcarecoreJoint AWAIR ambispective real-world study on home support provider services for Positive Airway Pressure (PAP) therapy in obstructive sleep apnea, conducted across France, Belgium, Spain and Portugal (~150,000 eligible participants), using Sanoïa's decentralized digital platform and Air Liquide Healthcare's patient follow-up data.
- AFCROs / Patient associations working groupcoreSanoïa leads the AFCROs / patient associations working group ("Les Patients dans la Recherche Clinique") to promote early, transparent participation of patient associations in clinical research design.
- Diabète LAB (Fédération Française des Diabétiques)minorDeployment of the "Diabèt'Acteur" platform with the Diabète LAB (Fédération Française des Diabétiques) to enable innovative, secure participation of diabetic patients in epidemiological and clinical research projects (e.g., SFDT1 cohort).
Scale indicators10 records
Recent moves6 records
Expansion highlights7 records
Sanoïa competitors and assessment
Company assessmentRegional players
- Observia: French digital health company providing eCOA, patient engagement and real-world evidence solutions for pharma and MedTech sponsors. Closely comparable to Sanoïa's patient-experience, questionnaires and digital CRO positioning, with similar geographic anchor in France and Europe.
- Owkin: French AI-for-health company applying machine learning to real-world patient data (notably from French hospitals) for pharma R&D. Comparable to Sanoïa as a French health-AI player leveraging national health data assets for sponsors, though Owkin is software/AI-first rather than a CRO service.
Emerging players
- Castor EDC: Electronic data capture and decentralized clinical trial platform used by sponsors and CROs. Comparable to Sanoïa's e-CRF and investigator portal capabilities, focused on technology rather than full-service CRO delivery, with overlap in academic and MedTech sponsors.
- Clinerion: Real-world patient data and analytics provider for clinical research, including protocol feasibility and patient identification across hospital networks. Comparable to Sanoïa's real-world e-cohort and SNDS analytics offering, but operating internationally rather than France-centric.
- TriNetX: Real-world data network and analytics platform for clinical research, used by pharma/biotech sponsors and CROs to design and run real-world studies. Comparable to Sanoïa's SNDS/e-cohorte analytics layer, focused on global federated RWD rather than a French national-claims anchor.
Broad incumbents
- IQVIA: Global #1 CRO with a dedicated real-world evidence and analytics business. Comparable to Sanoïa as a CRO serving pharma/biotech sponsors with real-world study services, but at vastly larger scale and with a much broader portfolio (clinical, technology, consulting).
- Syneos Health: Biopharmaceutical services organization with dedicated real-world and late-phase offerings. Comparable to Sanoïa as a CRO delivering real-world evidence and decentralized studies, but with substantially broader scale and a global site network.
- ICON plc: Top-5 global CRO with real-world evidence and late-phase research services. Comparable to Sanoïa's RWE / non-interventional study positioning, but operating at global scale across all phases and therapeutic areas.
- Parexel: Large global CRO with real-world data and late-phase capabilities acquired from major private equity. Overlaps with Sanoïa in real-world clinical study services for pharma and biotech sponsors, but covers the full clinical development spectrum.
Direct peers
- Medidata Solutions (Dassault Systèmes): Clinical trial technology platform providing eCRF, EDC, eCOA and decentralized trial infrastructure. Directly comparable to Sanoïa's e-CRF, patient portal and decentralized real-world study stack, though Medidata sells a horizontal technology platform rather than full-service CRO delivery.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks5 records
Key highlights7 records
Customer concentration
Sanoïa social profiles
Digital presenceSanoïa compliance and trust
Trust signalCompliance3 records
Sanoïa financial estimates
Financial estimateRevenue estimate
Valuation estimate
Sanoïa leadership team
Management profileNumber of profiles
Profiles3 records
Sanoïa funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Sanoïa M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Sanoïa
What does Sanoïa do?
Sanoïa is a digital Contract Research Organization (CRO) that designs, conducts and manages real-world clinical studies for pharmaceutical, biotech and MedTech sponsors. The company combines a proprietary digital platform (e-CRF, patient and investigator portals, multi-modal data capture) with full-service clinical operations (co-design, regulatory, medical writing, monitoring, biometrics, patient contact, SNDS/EGB analytics) to deliver decentralized, patient-centric real-world evidence studies in France and Europe.
Is Sanoïa a public or private company?
Sanoïa is a private company. It is classified as corporate owned and is currently acquired.
When was Sanoïa founded?
Sanoïa was founded in 2010. It employs 11 to 50 people.
Where is Sanoïa based?
Sanoïa is headquartered in Gémenos, France, in the Europe region.
How does Sanoïa make money?
Three revenue lines are on record. Full-service CRO contracts for real-world studies are the primary driver. The others are managed digital CRO services (managed services for sponsors) and specialized digital & patient-experience solutions.
Who are Sanoïa's main competitors?
Regional players on record are Observia and Owkin. Emerging players are Castor EDC, Clinerion and TriNetX. Broad incumbents are IQVIA, Syneos Health, ICON plc and Parexel. Medidata Solutions (Dassault Systèmes) is listed as a direct peer.
Does Sanoïa have an API?
No public API is recorded for Sanoïa.
What industry is Sanoïa in?
Sanoïa's product category is Contract Research Organization (CRO) Services. Its primary akta.pro industry code is HLAGAAAA, Clinical CROs (Phase I–IV), with a secondary code of HLAGAAAL, Specialty Therapeutic-Area CROs (e.g., oncology/rare disease). Its NAICS code is 5417 and its SIC code is 8700.